Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ZAP70 | P43403 | 16/20 | 0.69 |
| ▸ | FER | P16591 | 1/20 | 0.40 |
| ▸ | WEE1 | P30291 | 1/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6520669 | 1.00 | ZAP70 (0.69) | ZAP70FERWEE1LRRK2JAK2 | |
| SCHEMBL1158391 | 0.89 | ZAP70 (0.64) | ZAP70FERWEE1JAK1 | |
| SCHEMBL1158390 | 0.89 | ZAP70 (0.64) | ZAP70FERWEE1JAK1 | |
| SCHEMBL6520428 | 0.84 | ZAP70 (0.71) | ZAP70FERLRRK2JAK1 | |
| SCHEMBL1157949 | 0.84 | ZAP70 (0.70) | ZAP70FERLRRK2JAK2JAK1 | |
| SCHEMBL1158180 | 0.83 | ZAP70 (0.71) | ZAP70FERLRRK2JAK1 | |
| SCHEMBL1158787 | 0.83 | ZAP70 (0.69) | ZAP70FERLRRK2JAK2JAK1 | |
| SCHEMBL6517998 | 0.82 | ZAP70 (0.70) | ZAP70FERLRRK2JAK1 | |
| SCHEMBL1048432 | 0.82 | ZAP70 (1.00) | ZAP70FER | |
| SCHEMBL1158156 | 0.82 | ZAP70 (0.67) | ZAP70FERJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110053897-A1 | COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS | IRM LLC (BM) | 2011-03-03 | — | — | US | claimed |
| US-20110053897-A1 | COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS | IRM LLC (BM) | 2011-03-03 | — | — | US | disclosed |
| US-20110053897-A1 | COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS | IRM LLC (BM) | 2011-03-03 | — | — | US | disclosed |
| US-20110053897-A1 | COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS | IRM LLC (BM) | 2011-03-03 | — | — | US | disclosed |
| WO-2011014515-A1 | 2, 7 -NAPHTHYRIDIN- 1 -ONE DERIVATIVES AS SYK KINASE INHIBITORS | IRM LLC (BM) | 2011-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053897-A1 | COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS | SYK, BTK, LYN | ZAP70 5/4885FER 89/4885WEE1 2351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.